Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.

Yutaka Yasui Masayuki Kurosaki Kaoru TsuchiyaYuka HayakawaChitomi HasebeMasami AbeChikara OgawaKouji JokoHironori OchiToshifumi TadaShinichiro NakamuraKoichiro FurutaHiroyuki KimuraKeiji TsujiYuji KojimaTakehiro AkahaneTakashi TamadaYasushi UchidaMasahiko KondoAkeri MitsudaNamiki Izuminull null

Published in: Cancers (2022)

Ramucirumab is useful as a second-line therapy and feasible as a third- or later-line treatment for HCC.

Keyphrases

electronic health record
stem cells
big data
machine learning
cell therapy
combination therapy